Non-oncology Biopharmaceuticals Market is Segmented By Product Type (Biologics, Biosimilars), By Application (Immunology, Endocrinology, Others), By Region (North America, South America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030
Non-Oncology Biopharmaceuticals Market size is estimated to reach at a high CAGR of 10.4% during the forecast period (2023-2030).
Biopharmaceuticals are part of the wider category of therapeutic agents called biologics. Biopharmaceuticals are substances developed in living systems with the help of biotechnology and are used in therapeutic and diagnostic applications. Non-oncology biopharmaceuticals are the drugs used to treat various diseases rather than cancer, such as rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, hemophilia, age-related macular degeneration, osteoporosis, and others.
Non-oncology Biopharmaceuticals Market
|
Metrics |
Details |
|
Market CAGR |
10.4% |
|
Segments Covered |
By Product Type, By Application, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
To Get a Free Sample Click here
Non-oncology Biopharmaceuticals Market Dynamics
The global non-oncology biopharmaceuticals market growth is driven by the increasing launches, approvals, robust pipeline of novel biopharmaceuticals, increasing mergers and collaborations among key players.
Increasing launches, approvals, robust pipeline of novel biopharmaceuticals is expected to drive the growth in the forecast period
Frequent approvals, launches, and a robust pipeline of novel non-oncology biopharmaceuticals for various indications in the market are expected to support the U.S. non-oncology biopharmaceutical's market growth significantly. For instance, in September 2018, Eli Lilly and Company received the U.S. Food and Drug Administration (FDA) approval for its Emgality (galcanezumab-gnlm) 120 mg injection to prevent migraine in adults.
In February 2018, Novartis announced that the U.S. Food and Drug Administration (FDA) approved a label update for its Cosentyx (secukinumab), the first interleukin-17A (IL-17A) inhibitor approved to treat moderate-to-severe plaque psoriasis.
The high price of branded biological products is likely to hinder the market growth
According to the report published by the Association for Accessible Medicines in 2018, the annual treatment with Humira comes with a list price of US$ 38,000, and according to the report published by I-Mak.org, between 2012 and 2016, the average spending on Humira per person in U.S. increased from US$ 16,000 to US$ 33,000.
COVID-19 Impact Analysis
With the outbreak of COVID-19, the healthcare sector is adopting new technology that can help hospitals overcome the current pandemic and future medical emergencies. Owing to the growing adoption of new tools and technologies, the global biopharmaceutical fermentation systems market is projected to grow substantially during the coming years. COVID-19 has become a global pandemic and consumed more than a million lives. This has stimulated healthcare companies are developing innovative tools and technologies that can help doctors and medical officers to overcome present and future medical emergencies. For instance, In February 2021, Rentschler Biopharma; a Germany-based contract development and manufacturing organization (CDMO) announced to start commercial manufacture, formulation, and downstream processing of CVnCoV COVID-19 candidate vaccine by CureVac. Similarly, Bayer also announced to manufacture 160 million doses of CVnCoV in 2022. Owing to this, the global biopharmaceutical fermentation systems market is projected to grow exponentially in the coming years.
Global Non-oncology Biopharmaceuticals Market- Segment Analysis
The biologics segment is expected to hold the largest share in this market segment
Biologic drugs are used in the treatment of major chronic diseases like autoimmune diseases, which has enabled big pharmaceutical companies, like Eli Lilly and Company, Bristol-Myers Squibb, Novartis, AstraZeneca, and GlaxoSmithKline (GSK), to invest in these products. In 2019, three biological drugs were approved by the United States Food and Drug Administration (FDA), one of which is an anticoagulant solution by Griffons.
There are also increasing investments that have helped in driving the overall market growth. Novartis AG invested around USD 700 million in its biologics facility in Singapore, and Bristol-Myers Squibb invested nearly USD 900 million in an Irish large-scale biologics facility which was expected to be completed by 2019.
Furthermore, biologics prove efficient in treating rheumatoid arthritis and Crohn’s disease, which boosts the market even further.
Non-oncology Biopharmaceuticals Market Geographical Analysis
North America region holds the largest market share of global non-oncology biopharmaceuticals market
North American market has dominated the global non-oncology biopharmaceuticals market, and it is estimated to show a similar trend during the forecast period. The primary factors driving the market are the increasing incidences of chronic diseases, well-established pharmaceutical companies, and an increase in biotech companies.
With the rising COVID-19 pandemic, US-based companies are racing to develop vaccines against COVID-19. For instance, in March 2020, a Phase 1 clinical trial began at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle to evaluate an investigational vaccine designed to protect against COVID-19. The vaccine is being developed by NIAID scientists and their collaborators at the biotechnology company Moderna Inc.
For instance, in August 2020, Biocon Biologics India, a fully integrated biosimilars company and a subsidiary of Biocon Ltd, and Mylan NV announced the US launch of Semglee (insulin glargine injection). Hence, all these factors are found to boost the overall market growth in the region.
Non-oncology Biopharmaceuticals Market Competitive Landscape
The global non-oncology biopharmaceuticals market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Eli Lilly and Company, GlaxoSmithKline, Novartis, Amgen Inc, AbbVie Inc, AstraZeneca, Novo Nordisk A/S, Takeda Pharmaceutical Company Ltd, Elusys Therapeutics and Swedish Orphan Biovitrum. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market. For instance, Leadiant Biosciences, Inc. got FDA approval for its Revcov (elapegademase-lvlr) injection in the United States in October 2018. Revcovi is a new enzyme replacement therapy (ERT) for pediatric and adult patients with adenosine deaminize severe combination immune deficiency (ADA-SCID).
Non-oncology Biopharmaceuticals Market – Key Companies to Watch
Novartis AG
Overview: Novartis AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland established in 1996. It operates business through two divisions: Innovative medicine, Sandoz, made up of two business units – Novartis Pharmaceuticals which includes Novartis Gene Therapies, and Novartis Oncology.
Product Portfolio: It includes product like Cosentyx (secukinumab) for the treatment of active enthesitis-related arthritis (ERA) in four years and older, and active juvenile psoriatic arthritis (JPsA) in patients two years and older.
Frequently Asked Questions
What is the Projected CAGR value of the Non-oncology Biopharmaceuticals Market?
Non-oncology Biopharmaceuticals Market is expected to grow at a CAGR of 10.4% during the forecasting period 2022-2029.
Which region controlled the global market during 2022-2029?
North America region Controls the Non-oncology Biopharmaceuticals Market during 2022-2029
Which is the fastest growing region in the Non-oncology Biopharmaceuticals Market?
Among all regions, Asia Pacific is the fastest growing market share during the forecast period